In subjects with type 2 @entity6 in whom an impaired response to an endothelial-dependent vasodilator has been characterized, the populations have also been at least moderately @entity28 . @entity28 has been characterized as an independent predictor of @entity409 in nondiabetic subjects. We hypothesized that in normotensive subjects with type 2 @entity6 compared with age-matched control subjects, 1) endothelium-dependent vasodilation, as demonstrated by the @entity450 ( @entity450 ) response to intraarterial @entity934 , would be decreased; 2) endothelium-independent vasodilation, as demonstrated by the @entity450 response to intraarterial @entity1854 , would be similar; 3) the degree of insulin resistance, as measured by the insulin sensitivity index (SI), would predict greater impairment in the @entity450 response to @entity934 ; and 4) these relationships would be independent of @entity28 . We measured @entity450 by @entity432 plethysmography during brachial arterial infusions of the endothelium-dependent vasodilator @entity934 and the endothelium-independent vasodilator @entity1854 in 20 control and 17 subjects with type 2 @entity6 . We measured SI using the frequently sampled i.v. @entity413 tolerance test. Among the diabetic relative to the control subjects we identified a decrease in the @entity934 -mediated percent increase in @entity450 (P = 0.02). Using the absolute @entity450 response to @entity934 and including adjustments for body mass index and other covariates, the overall group difference remained and was noted to be greatest in those subjects who had lower baseline FABFs. In contrast, no significant difference in the @entity1854 -mediated increase in the percent change @entity450 was identified between groups (P = 0.30). Finally, the degree of insulin resistance, as measured by SI, did not independently predict greater impairment of the @entity450 response to @entity934 . This study is the first to identify specific endothelial cell dysfunction that remains significant after adjustment for @entity28 in a population of normotensive subjects with type 2 @entity6 .

Specific impairment of endothelium-dependent vasodilation in subjects with type 2 XXXX independent of @entity28 .

@entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'obese', 'obesity'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity1854 :: ('MESH:D009599', 'Chemical') :: ['nitroprusside'] @entity450 :: ('MESH:D006940', 'Disease') :: ['FABF', 'forearm blood flow'] @entity432 :: ('MESH:D001157', 'Disease') :: ['venous occlusion'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
